Personal information

diabetes, insulin resistance, insulin secretion
Italy

Biography

Dr. Del Prato was Professor of Endocrinology and Metabolism at the University of Pisa School of Medicine and Chief of the Section of Diabetes, University of Pisa, Italy. He currently held the position of Affiliate Professore, Interdisciplinary Research Center "Health Science" of the Sant'Anna School of Advanced Studies non Pisa, Italy. He graduated MD cum laude from the University of Padova and undertook post graduate specialization in both Endocrinology and Internal Medicine. From 1988 through 1990 he was Associate Professor at the University of Texas, Health Science Center, San Antonio, TX, USA.
Dr. Del Prato's research interests have always been focused on diabetes and in particular the physiopathology and therapy of type 2 diabetes and insulin resistance syndrome. He is a member of many societies and associations including the European Association for the Study of Diabetes, the American Diabetes Association, the Mediterranean Group for the Study of Diabetes, the International Diabetes Federation. He is past-President and now Honorary President of the Italian Society of Diabetology, past-Vice President of the European Association for the Study of Diabetes (EASD), and Chairman of the European Foundation for the Study of Diabetes. Currently he is President of the EASD. He has served as Chairman of the Scientific Committee of the World Diabetes Congress in Dubai 2011. He acts as a referee for numerous major journals. Furthermore, Dr. Del Prato has served on the Editorial Boards for the Journal of Endocrinological Investigation, Diabetes, Nutrition, and Metabolism, the European Journal of Clinical Investigation (Diabetes and Metabolism section) Diabetes/Metabolism Research & Reviews, Diabetes et Metabolism, Journal of Clinical Endocrinology and Metabolism, Journal of Diabetes and its Complications and Diabetes Care and, presently, for Acta Diabetologica, Diabetes & Vascular Disease Research, Journal of Endocrinology, and Endocrine Connection. Dr. Del Prato has published over 700 articles on national and international journals (>540 listed in PubMed) and has been awarded several honors, including the Prize of the Italian Society of Diabetology for outstanding scientific activity, the Honorary Professorship at the Universidad Peruana Cayetano Heredya in Lima, the 10th Lifetime Contribution Oration Award from the Madras Diabetes Research Foundation, India. He has been bestowed the honor of Commander of the Order of the Italian Republic for Scientific Merits.

Activities

Employment (8)

Fondazione Toscana Gabriele Monasterio: Pisa, IT

2024-01-11 to present | Affilate Prpfessor
Employment
Source: Self-asserted source
Stefano Del Prato

Sant'Anna School of Advanced Studies: Pisa, Tuscany, IT

2022-11-01 to present | Affiliate Professor (Interdisciplinary Research Center "Health Science")
Employment
Source: Self-asserted source
Stefano Del Prato

Università degli Studi di Pisa: Pisa, Toscana, IT

2002-11-01 to 2022-10-31 | Full Professor of Endocrinology (Department of Clinical and Experimental Medicine)
Employment
Source: Self-asserted source
Stefano Del Prato

Università degli Studi di Pisa Facoltà di Medicina e Chirurgia: Pisa, Toscana, IT

2000-11-01 to 2002-10-31 | Associate Professor of Endocrinology
Employment
Source: Self-asserted source
Stefano Del Prato

Università degli Studi di Padova: Padova, IT

1992-11-02 to 2000-10-31 | Associate Professor of Endocrinology
Employment
Source: Self-asserted source
Stefano Del Prato

Ospedale Civile di Padova: Padova, IT

1987-11-11 to 1992-10-31 | Aiuto Corresponsabile
Employment
Source: Self-asserted source
Stefano Del Prato

The University of Texas Health Science Center at San Antonio Official Bookstore: San Antonio, TX, US

1988-10-01 to 1990-04-30 | Associate professor (Medicine)
Employment
Source: Self-asserted source
Stefano Del Prato

Ospedale Civile di Padova: Padova, IT

1982-02-04 to 1987-11-10 | Assistente Medico
Employment
Source: Self-asserted source
Stefano Del Prato

Education and qualifications (4)

University of Padova: Padova, IT

1982-11-05 to 1987-07-10 | Post-Graduate Specialization in Internal Medicine
Education
Source: Self-asserted source
Stefano Del Prato

Yale University: New Haven, CT, US

1984-05-01 to 1985-04-30 | Postdoctoral Fellow (Internal Medicine (Endocrinology))
Education
Source: Self-asserted source
Stefano Del Prato

University of Padova: Padova, IT

1979-02-27 to 1981-07-14 | Post-Graduate Specialization in Endocrinology
Education
Source: Self-asserted source
Stefano Del Prato

University of Padova: Padova, IT

1971-11-02 to 1978-03-20 | MD
Education
Source: Self-asserted source
Stefano Del Prato

Professional activities (7)

Italian Society of Diabetes: Rome, IT

2018-05-18 to present | Celsius Prize
Invited position
Source: Self-asserted source
Stefano Del Prato

Italian Society of Diabetes: Rome, IT

2017-03-14 to present | Honorary President
Invited position
Source: Self-asserted source
Stefano Del Prato

Universidad Peruana Cayetano Heredia: Lima, PE

2012-08-23 to present | Honorary Professor
Invited position
Source: Self-asserted source
Stefano Del Prato

European Association for the Study of Diabetes: Dusseldorf, Nordrhein-Westfalen, DE

2020-01-01 to 2022-12-31 | President
Invited position
Source: Self-asserted source
Stefano Del Prato

European Foundation for the Study of Diabetes: Dusseldorf, DE

2014-09 to 2019-12 | Chairman
Invited position
Source: Self-asserted source
Stefano Del Prato

European Association for the Study of Diabetes: Dusseldorf, Nordrhein-Westfalen, DE

2011-09 to 2014-09 | Vice-President
Invited position
Source: Self-asserted source
Stefano Del Prato

Italian Society of Diabetes: Roma, IT

2012-06-01 to 2014-06-30 | President
Distinction
Source: Self-asserted source
Stefano Del Prato

Works (50 of 438)

Items per page:
Page 1 of 9

Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis

Circulation: Heart Failure
2025-01-30 | Journal article
Contributors: W.H. Wilson Tang; Yuxi Liu; Javed Butler; Stefano Del Prato; Justin A. Ezekowitz; Nasrien E. Ibrahim; Carolyn S.P. Lam; Thomas H. Marwick; Riccardo Perfetti; Julio Rosenstock et al.
Source: check_circle
Crossref

Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review

Diabetes, Obesity and Metabolism
2025-01-28 | Journal article
Contributors: Alice Y. Y. Cheng; Robert J. Heine; Stefano Del Prato; Jennifer B. Green; Vivian Thuyanh Thieu; Meltem Zeytinoglu
Source: check_circle
Crossref

Beta-cell, but not autonomic nervous system, function is related to MAFLD in early stages of glucose intolerance

BMJ Open Diabetes Research & Care
2024-12 | Journal article
Contributors: Rumyana Dimova; Nevena Chakarova; Mina Serdarova; Cvetelina Marinova; Dimitar Popov; Stefano Del Prato; Tsvetalina Tankova
Source: check_circle
Crossref

Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐O trial

Diabetes, Obesity and Metabolism
2024-12 | Journal article
Contributors: Hertzel C. Gerstein; Mu Yang; Shun Fu Lee; Kelley R. H. Branch; Stefano Del Prato; Carolyn S. P. Lam; Renato D. Lopes; Richard Pratley; Julio Rosenstock; Naveed Sattar
Source: check_circle
Crossref

Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment

New England Journal of Medicine
2024-12-12 | Journal article
Contributors: Carol Wysham; Harpreet S. Bajaj; Stefano Del Prato; Denise Reis Franco; Arihiro Kiyosue; Dominik Dahl; Chunmei Zhou; Molly C. Carr; Michael Case; Livia Firmino Gonçalves
Source: check_circle
Crossref

Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care

Diabetologia
2024-11 | Journal article
Contributors: Gian Paolo Fadini; Enrico Longato; Mario Luca Morieri; Enzo Bonora; Agostino Consoli; Bruno Fattor; Mauro Rigato; Federica Turchi; Stefano Del Prato; Angelo Avogaro et al.
Source: check_circle
Crossref

The role of incretin receptor agonists in the treatment of obesity

Diabetes, Obesity and Metabolism
2024-10 | Journal article
Contributors: Thomas Forst; Christophe De Block; Stefano Del Prato; Sara Armani; Juan Frias; Anne Lautenbach; Bernhard Ludvik; Marina Marinez; Chantal Mathieu; Timo D. Müller et al.
Source: check_circle
Crossref

2024: The year to take European action on diabetes to the next level

Diabetologia
2024-07 | Journal article
Contributors: Stefano Del Prato; Bart Torbeyns; Chantal Mathieu
Source: check_circle
Crossref

Continuous glucose monitoring for the routine care of type 2 diabetes mellitus

Nature Reviews Endocrinology
2024-07 | Journal article
Contributors: Ramzi A. Ajjan; Tadej Battelino; Xavier Cos; Stefano Del Prato; Jean-Christophe Philips; Laurent Meyer; Jochen Seufert; Samuel Seidu
Source: check_circle
Crossref

The current landscape for diabetes treatment: Preventing diabetes-associated CV risk

Atherosclerosis
2024-07 | Journal article
Contributors: Angela Dardano; Cristina Bianchi; Monia Garofolo; Stefano Del Prato
Source: check_circle
Crossref

β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin

Diabetes Care
2024-07-01 | Journal article
Contributors: Giuseppe Daniele; Andrea Tura; Alex Brocchi; Alessandro Saba; Beatrice Campi; Veronica Sancho-Bornez; Angela Dardano; Stefano Del Prato
Source: check_circle
Crossref

Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial

Diabetes, Obesity and Metabolism
2024-04 | Journal article
Contributors: Hertzel C. Gerstein; Rajibul Mian; Chinthanie Ramasundarahettige; Kelley R. H. Branch; Stefano Del Prato; Carolyn S. P. Lam; Renato D. Lopes; Richard Pratley; Julio Rosenstock; Naveed Sattar
Source: check_circle
Crossref

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

Diabetes Care
2023-11-01 | Journal article
Contributors: Julio Rosenstock; Luis Vázquez; Stefano Del Prato; Denise Reis Franco; Govinda Weerakkody; Biyue Dai; Laura Fernández Landó; Brandon K. Bergman; Angel Rodríguez
Source: check_circle
Crossref

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Diabetologia
2023-10 | Journal article
Contributors: Anna Solini; Domenico Tricò; Stefano Del Prato
Source: check_circle
Crossref

Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial

Circulation
2023-03-28 | Journal article
Contributors: Hertzel C. Gerstein; Zhuoru Li; Chinthanie Ramasundarahettige; Seungjae Baek; Kelley R.H. Branch; Stefano Del Prato; Carolyn S.P. Lam; Renato D. Lopes; Richard Pratley; Julio Rosenstock et al.
Source: check_circle
Crossref

The European Diabetes Forum (EUDF): a forum for turning the tide on diabetes in Europe

Diabetologia
2023-02 | Journal article
Contributors: Chantal Mathieu; Jeannette Soderberg; Stefano Del Prato; Anne-Marie Felton; Xavier Cos; Carine de Beaufort; Jean-François Gautier; Bastian Hauck; Angus Forbes; Robert Heine et al.
Source: check_circle
Crossref

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetologia
2022-12 | Journal article
Contributors: Melanie J. Davies; Vanita R. Aroda; Billy S. Collins; Robert A. Gabbay; Jennifer Green; Nisa M. Maruthur; Sylvia E. Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone et al.
Source: check_circle
Crossref

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes Care
2022-11-01 | Journal article
Contributors: Melanie J. Davies; Vanita R. Aroda; Billy S. Collins; Robert A. Gabbay; Jennifer Green; Nisa M. Maruthur; Sylvia E. Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone et al.
Source: check_circle
Crossref

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Diabetologia
2022-08 | Journal article
Contributors: Thomas Karagiannis; Ioannis Avgerinos; Aris Liakos; Stefano Del Prato; David R. Matthews; Apostolos Tsapas; Eleni Bekiari
Source: check_circle
Crossref

Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors

Diabetes, Obesity and Metabolism
2022-02 | Journal article
Contributors: Gian Paolo Fadini; Stefano Del Prato; Angelo Avogaro; Anna Solini
Source: check_circle
Crossref

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Circulation
2022-02-22 | Journal article
Contributors: Carolyn S.P. Lam; Chinthanie Ramasundarahettige; Kelley R.H. Branch; Naveed Sattar; Julio Rosenstock; Richard Pratley; Stefano Del Prato; Renato D. Lopes; Elisabeth Niemoeller; Nardev S. Khurmi et al.
Source: check_circle
Crossref

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening

Diabetes, Obesity and Metabolism
2021-06 | Journal article
Contributors: Julio Rosenstock; Lawrence Blonde; Vanita R. Aroda; Juan Frias; Elisabeth Souhami; Chen Ji; Elisabeth Niemoeller; Stefano Del Prato
Source: check_circle
Crossref

Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141

Diabetes Care
2021-04-01 | Journal article
Contributors: Monia Garofolo; Elisa Gualdani; Cristina Bianchi; Michele Aragona; Fabrizio Campi; Daniela Lucchesi; Giuseppe Daniele; Roberto Miccoli; Paolo Francesconi; Stefano Del Prato et al.
Source: check_circle
Crossref

Tackling obesity during the COVID‐19 pandemic

Diabetes/Metabolism Research and Reviews
2021-03 | Journal article
Contributors: Amit Akirov; Avivit Cahn; Stefano Del Prato; Philip Home; Luc Van Gaal; Juliana Chan; Guang Ning; Itamar Raz
Source: check_circle
Crossref

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Diabetes Care
2021-03-01 | Journal article
Contributors: Lawrence Blonde; Julio Rosenstock; Juan Frias; Andreas L. Birkenfeld; Elisabeth Niemoeller; Elisabeth Souhami; Chen Ji; Stefano Del Prato; Vanita R. Aroda
Source: check_circle
Crossref

Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

Diabetes Care
2021-03-01 | Journal article
Contributors: Andrea Giaccari; Anna Solini; Simona Frontoni; Stefano Del Prato
Source: check_circle
Crossref

Design and baseline characteristics of the AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist

Diabetes, Obesity and Metabolism
2021-02 | Journal article
Contributors: Hertzel C. Gerstein; Kelley Branch; Laura Heenan; Stefano Del Prato; Nardev S. Khurmi; Carolyn S. P. Lam; Richard Pratley; Julio Rosenstock; Naveed Sattar
Source: check_circle
Crossref

Early combination therapy delayed treatment escalation in newly diagnosed young‐onset type 2 diabetes: A subanalysis of the VERIFY study

Diabetes, Obesity and Metabolism
2021-01 | Journal article
Contributors: Juliana C. N. Chan; Päivi M. Paldánius; Chantal Mathieu; Michael Stumvoll; David R. Matthews; Stefano Del Prato
Source: check_circle
Crossref

Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study

European Psychiatry
2021-01-08 | Journal article
Contributors: Silvana Galderisi; Marc De Hert; Stefano Del Prato; Andrea Fagiolini; Philip Gorwood; Stefan Leucht; Aldo Pietro Maggioni; Armida Mucci; Celso Arango
Source: check_circle
Crossref

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Diabetes, Obesity and Metabolism
2020-09 | Journal article
Contributors: Stefano Del Prato; Juan Pablo Frias; Lawrence Blonde; Vanita R. Aroda; Niam Shehadeh; Aramesh Saremi; Terry Dex; Elisabeth Niemoeller; Elisabeth Souhami; Minzhi Liu et al.
Source: check_circle
Crossref

Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters

Diabetes Care
2020-08-01 | Journal article
Contributors: Jamie Hartmann-Boyce; Elizabeth Morris; Clare Goyder; Jade Kinton; James Perring; David Nunan; Kamal Mahtani; John B. Buse; Stefano Del Prato; Linong Ji et al.
Source: check_circle
Crossref

Efficacy and safety of once‐monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo‐controlled, 16‐week randomized dose‐finding study

Diabetes, Obesity and Metabolism
2020-07 | Journal article
Contributors: Stefano Del Prato; Jahoon Kang; Michael E. Trautmann; John Stewart; Christopher H. Sorli; Michael Derwahl; Alfonso Soto; Kun‐Ho Yoon
Source: check_circle
Crossref

Effects of treatment with metformin and/or sitagliptin on beta‐cell function and insulin resistance in prediabetic women with previous gestational diabetes

Diabetes, Obesity and Metabolism
2020-04 | Journal article
Contributors: Giuseppe Daniele; Andrea Tura; Angela Dardano; Alessandra Bertolotto; Cristina Bianchi; Laura Giusti; Jancy Joseph Kurumthodathu; Stefano Del Prato
Source: check_circle
Crossref

How conclusive is the CONCLUDE trial?

Diabetologia
2020-04-16 | Journal article
Contributors: Stefano Del Prato
Source: check_circle
Crossref

Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming

Diabetes Care
2020-03-01 | Journal article
Contributors: Angelo Avogaro; Gian Paolo Fadini; Stefano Del Prato
Source: check_circle
Crossref

Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study

Cardiovascular Diabetology
2019-12 | Journal article
Contributors: Monia Garofolo; Elisa Gualdani; Rosa Giannarelli; Michele Aragona; Fabrizio Campi; Daniela Lucchesi; Giuseppe Daniele; Roberto Miccoli; Paolo Francesconi; Stefano Del Prato et al.
Source: check_circle
Crossref

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, Obesity and Metabolism
2019-11 | Journal article
Contributors: Clifford J. Bailey; Stefano Del Prato; Cheryl Wei; Daniel Reyner; Gabriela Saraiva
Source: check_circle
Crossref

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial

Diabetes Care
2019-11-01 | Journal article
Contributors: Lawrence Blonde; Julio Rosenstock; Stefano Del Prato; Robert Henry; Naim Shehadeh; Juan Frias; Elisabeth Niemoeller; Elisabeth Souhami; Chen Ji; Vanita R. Aroda
Source: check_circle
Crossref

A pre‐specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM

Diabetes, Obesity and Metabolism
2019-10 | Journal article
Contributors: David R. Matthews; Päivi M. Paldánius; Michael Stumvoll; Jackie Han; Giovanni Bader; YannTong Chiang; Pieter Proot; Stefano Del Prato
Source: check_circle
Crossref

Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people

Primary Care Diabetes
2019-08 | Journal article
Contributors: C.E. Hambling; K. Khunti; X. Cos; J. Wens; L. Martinez; P. Topsever; S. Del Prato; A. Sinclair; G. Schernthaner; G. Rutten et al.
Source: check_circle
Crossref

Sustained 52‐week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes

Diabetes, Obesity and Metabolism
2019-04 | Journal article
Contributors: Yehuda Handelsman; Chantal Mathieu; Stefano Del Prato; Eva Johnsson; Raisa Kurlyandskaya; Nayyar Iqbal; Ricardo Garcia‐Sanchez; Julio Rosenstock
Source: check_circle
Crossref

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study

Diabetes, Obesity and Metabolism
2019-02 | Journal article
Contributors: Gian Paolo Fadini; Anna Solini; Maria Laura Manca; Giuseppe Penno; Adriano Gatti; Roberto Anichini; Stefano Del Prato; Angelo Avogaro
Source: check_circle
Crossref

Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach

Journal of Diabetes and its Complications
2019-01 | Journal article
Contributors: Cristina Bianchi; Michele Aragona; Cosimo Rodia; Walter Baronti; Giovanni de Gennaro; Alessandra Bertolotto; Stefano Del Prato
Source: check_circle
Crossref

Type 2 Diabetes Mellitus. From the start – combination therapy

Diabetes mellitus
2018-12-17 | Journal article
Contributors: Francesco Indovina; Pierpaolo Falcetta; Stefano Del Prato
Source: check_circle
Crossref

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

Diabetes, Obesity and Metabolism
2018-11 | Journal article
Contributors: Paola Fioretto; Stefano Del Prato; John B. Buse; Ronald Goldenberg; Francesco Giorgino; Daniel Reyner; Anna Maria Langkilde; C. David Sjöström; Peter Sartipy
Source: check_circle
Crossref

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme

Diabetes, Obesity and Metabolism
2018-08 | Journal article
Contributors: Chantal Mathieu; Stefano Del Prato; Fady T. Botros; Vivian T. Thieu; Imre Pavo; Nan Jia; Axel Haupt; Chrisanthi A. Karanikas; Luis‐Emilio García‐Pérez
Source: check_circle
Crossref

Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality

Journal of Diabetes and its Complications
2018-06 | Journal article
Contributors: Monia Garofolo; Eleonora Russo; Roberto Miccoli; Daniela Lucchesi; Laura Giusti; Veronica Sancho-Bornez; Giuseppe Daniele; Stefano Del Prato; Giuseppe Penno
Source: check_circle
Crossref

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin

Diabetes, Obesity and Metabolism
2018-06 | Journal article
Contributors: Stefano Del Prato; Julio Rosenstock; Ricardo Garcia‐Sanchez; Nayyar Iqbal; Lars Hansen; Eva Johnsson; Hungta Chen; Chantal Mathieu
Source: check_circle
Crossref

Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors

Diabetes, Obesity and Metabolism
2018-04 | Journal article
Contributors: Stefano Del Prato; Robert Chilton
Source: check_circle
Crossref

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

Diabetes, Obesity and Metabolism
2017-12 | Journal article
Contributors: Lawrence A. Leiter; Bertrand Cariou; Dirk Müller‐Wieland; Helen M. Colhoun; Stefano Del Prato; Francisco J. Tinahones; Kausik K. Ray; Maja Bujas‐Bobanovic; Catherine Domenger; Jonas Mandel et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 9

Peer review (12 reviews for 6 publications/grants)

Review activity for Advanced science. (1)
Review activity for Cell metabolism. (1)
Review activity for Endocrine reviews. (1)
Review activity for Nature medicine. (1)
Review activity for The journal of clinical endocrinology and metabolism. (2)
Review activity for The Lancet. (6)